Nordwand Advisors, LLC Lexicon Pharmaceuticals, Inc. Transaction History
Nordwand Advisors, LLC
- $243 Billion
- Q4 2024
A detailed history of Nordwand Advisors, LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Nordwand Advisors, LLC holds 4,000 shares of LXRX stock, worth $1,440. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,000
Previous 4,000
-0.0%
Holding current value
$1,440
Previous $6.28 Million
52.96%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
133Shares Held
245MCall Options Held
52KPut Options Held
178K-
Artal Group S.A. Luxembourg, N4136MShares$49 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$14 Million1.27% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$3.56 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.88MShares$3.56 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.99MShares$3.24 Million0.02% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $67.9M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...